StockMacro
Company, fund or insider

Help

Menu

C4 Therapeutics

$2.48 -29% in 6 monthsMarket cap $325.7M

CCCC on XNAS, Health Care, C4 Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Short interest is 35% of shares, 8.2 times its level a year earlier, while quarterly revenue fell 25%.

  • BadNet loss $91.1M over 12 months; cash $274.7M
  • BadShares fell 22% in one month and 30% in six months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
104
Website
c4therapeutics.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $8.5M, net loss $21.8M.
Quarter to 31 Dec 2021: revenue $20.1M, net income -$15.7MQuarter to 31 Dec 2021: revenue $20.1M, net income -$15.7MQuarter to 31 Mar 2022: revenue $7.7M, net income -$31.6MQuarter to 31 Mar 2022: revenue $7.7M, net income -$31.6MQuarter to 30 Jun 2022: revenue $13.8M, net income -$27.4MQuarter to 30 Jun 2022: revenue $13.8M, net income -$27.4MQuarter to 30 Sep 2022: revenue $6.8M, net income -$32.0MQuarter to 30 Sep 2022: revenue $6.8M, net income -$32.0MQuarter to 31 Dec 2022: revenue $2.9M, net income -$37.2MQuarter to 31 Dec 2022: revenue $2.9M, net income -$37.2MQuarter to 31 Mar 2023: revenue $3.8M, net income -$34.8MQuarter to 31 Mar 2023: revenue $3.8M, net income -$34.8MQuarter to 30 Jun 2023: revenue $2.7M, net income -$35.9MQuarter to 30 Jun 2023: revenue $2.7M, net income -$35.9MQuarter to 30 Sep 2023: revenue $11.1M, net income -$27.0MQuarter to 30 Sep 2023: revenue $11.1M, net income -$27.0MQuarter to 31 Dec 2023: revenue $3.3M, net income -$34.8MQuarter to 31 Dec 2023: revenue $3.3M, net income -$34.8MQuarter to 31 Mar 2024: revenue $3.0M, net income -$28.4MQuarter to 31 Mar 2024: revenue $3.0M, net income -$28.4MQuarter to 30 Jun 2024: revenue $12.0M, net income -$17.7MQuarter to 30 Jun 2024: revenue $12.0M, net income -$17.7MQuarter to 30 Sep 2024: revenue $15.4M, net income -$24.7MQuarter to 30 Sep 2024: revenue $15.4M, net income -$24.7MQuarter to 31 Dec 2024: revenue $5.2M, net income -$34.6MQuarter to 31 Dec 2024: revenue $5.2M, net income -$34.6MQuarter to 31 Mar 2025: revenue $7.2M, net income -$26.3MQuarter to 31 Mar 2025: revenue $7.2M, net income -$26.3MQuarter to 30 Jun 2025: revenue $6.5M, net income -$26.0MQuarter to 30 Jun 2025: revenue $6.5M, net income -$26.0MQuarter to 30 Sep 2025: revenue $11.2M, net income -$32.2MQuarter to 30 Sep 2025: revenue $11.2M, net income -$32.2MQuarter to 31 Dec 2025: revenue $11.0M, net income -$20.5MQuarter to 31 Dec 2025: revenue $11.0M, net income -$20.5MQuarter to 31 Mar 2026: revenue $6.2M, net income -$25.1MQuarter to 31 Mar 2026: revenue $6.2M, net income -$25.1MQuarter to 30 Jun 2026: revenue $6.6M, net income -$23.6MQuarter to 30 Jun 2026: revenue $6.6M, net income -$23.6MQuarter to 30 Sep 2026: revenue $8.5M, net income -$21.8MQuarter to 30 Sep 2026: revenue $8.5M, net income -$21.8M
31 Dec 2021RevenueNet incomeNet losstallest bar $37.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$8.5M-$21.8M
30 Jun 2026$6.6M-$23.6M
31 Mar 2026$6.2M-$25.1M
31 Dec 2025$11.0M-$20.5M
30 Sep 2025$11.2M-$32.2M
30 Jun 2025$6.5M-$26.0M
31 Mar 2025$7.2M-$26.3M
31 Dec 2024$5.2M-$34.6M
30 Sep 2024$15.4M-$24.7M
30 Jun 2024$12.0M-$17.7M
31 Mar 2024$3.0M-$28.4M
31 Dec 2023$3.3M-$34.8M
30 Sep 2023$11.1M-$27.0M
30 Jun 2023$2.7M-$35.9M
31 Mar 2023$3.8M-$34.8M
31 Dec 2022$2.9M-$37.2M
30 Sep 2022$6.8M-$32.0M
30 Jun 2022$13.8M-$27.4M
31 Mar 2022$7.7M-$31.6M
31 Dec 2021$20.1M-$15.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $32.3M $30.1M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +7.2% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$91.1M -$119.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.63 -$1.67
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -316% -431% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -282% -396% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -47.6% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $274.7M $199.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$274.7M (net cash) -$199.8M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.74
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 10.1 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.6 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
C4 TherapeuticsCCCC (this company) $325.7Mloss10.1+7.2%-282%
X4 PharmaceuticalsXFOR $306.3Mloss18.1-50%-475%
AlectorALEC $347.6M8.42.0+151%23.9%
TRex BioTRXB $297.0M––––
Precision BioSciencesDTIL $282.5Mloss6.3+6353%-85.6%
AgenusAGEN $270.1M8.82.0+25%23.0%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-25%

$8.5M vs $11.2M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$122K

bought $0, sold $122K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

0%

147 13F filers vs 147

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

137.5M shares held by 13F filers (30 Sep 2026) of 131.3M outstanding (30 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

35%

46.6M shares sold short (30 Oct 2026) of 131.3M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

15.1

46.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+9.0%

42.7M shares sold short in the report before, 46.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

34%

34% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

6

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

16

16 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.0×

16 articles in the last 7 days; its usual week has 2.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 34.0M, 8.2× a year earlier

Price $2.48 on 20 Nov 2026, +4.2% over 12 months (12-month range $1.71 to $4.67)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $145K in the last 12 months (the 12 months before: -$4K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $8.5M in the latest quarter, -25% on a year earlier.
Capital spending per quarter. Capital spending $37K in the latest quarter, -80% on a year earlier.
Institutional holders (13F filers). 147 13F filers reported holding it in the latest 13F quarter, +62% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
15 Sep 2026Sharp changeShort interest spike: short interest spike, 37.4M vs usual 8.0M (2026-08-31); 9.9x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 34.0M vs usual 7.3M (2026-08-14); 8.2x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 30.4M vs usual 7.2M (2026-07-31); 6.5x the same period a year earlier
16 Jun 2026Sharp changeShort interest spike: short interest spike, 21.7M vs usual 6.3M (2026-05-29); 3.5x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 21.3M vs usual 6.3M (2026-05-15); 3.3x the same period a year earlier
15 May 20268-K and other filingsDirector or officer change
15 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 May 2026Sharp changeShort interest spike: short interest spike, 21.1M vs usual 6.3M (2026-04-30); 3.3x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 21.0M vs usual 6.3M (2026-04-15); 2.7x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 16.2M vs usual 6.3M (2026-03-31); 2.1x the same period a year earlier
14 Apr 20258-K and other filingsDirector or officer change
14 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Nov 20248-K and other filingsDirector or officer change
5 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 15.4M vs usual 3.5M (2024-09-30); 1.4x the same period a year earlier
15 Oct 20248-K and other filingsDirector or officer change
11 Oct 20248-K and other filingsDirector or officer change
3 Sep 20248-K and other filingsDirector or officer change
6 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 12.0M vs usual 3.5M (2024-06-30); 4.5x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 11.6M vs usual 3.3M (2024-07-15); 5.2x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 14.5M vs usual 3.1M (2024-06-14); 4.4x the same period a year earlier
18 Jun 2024Sharp changeShort interest spike: short interest spike, 13.3M vs usual 3.1M (2024-05-31); 4.1x the same period a year earlier
10 Jun 20248-K and other filingsDirector or officer change
10 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 May 2024Sharp changeShort interest spike: short interest spike, 11.3M vs usual 2.9M (2024-05-15); 3.9x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 10.1M vs usual 2.9M (2024-04-30); 3.5x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 9.6M vs usual 2.9M (2024-04-15); 3.4x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 9.1M vs usual 2.7M (2024-03-28); 3.5x the same period a year earlier
8 Mar 20248-K and other filingsDirector or officer change
8 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Jan 20248-K and other filingsRestructuring costs announced
2 Jan 2024Sharp changeShort interest spike: short interest spike, 8.1M vs usual 2.7M (2023-12-15); 2.2x the same period a year earlier
20 Nov 20238-K and other filingsDirector or officer change
5 Sep 20238-K and other filingsDirector or officer change
20 Jun 20238-K and other filingsDirector or officer change
20 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Feb 20238-K and other filingsDirector or officer change
2 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Aug 2022Sharp changeShort interest spike: short interest spike, 5.2M vs usual 2.9M (2022-07-15); 2.0x the same period a year earlier
2 Aug 20228-K and other filingsDirector or officer change
19 Jul 2022Sharp changeShort interest spike: short interest spike, 5.1M vs usual 2.8M (2022-06-30); 1.8x the same period a year earlier
17 Jun 20228-K and other filingsDirector or officer change
17 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Jun 2022Sharp changeShort interest spike: short interest spike, 4.3M vs usual 2.8M (2022-05-31); 1.8x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 3.9M vs usual 2.7M (2022-05-13); 1.5x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 5.1M vs usual 2.7M (2022-04-29); 2.0x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 5.4M vs usual 2.7M (2022-04-14); 1.8x the same period a year earlier
12 Apr 2022Sharp changeShort interest spike: short interest spike, 5.1M vs usual 2.7M (2022-03-31); 1.4x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 4.7M vs usual 2.7M (2022-03-15); 2.3x the same period a year earlier
16 Mar 20228-K and other filingsDirector or officer change
16 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Mar 2022Sharp changeShort interest spike: short interest spike, 3.6M vs usual 2.7M (2022-02-28); 1.9x the same period a year earlier
Insider net buying (open market)
Month from 1 Dec 2021: -$23K published
Month from 1 Jan 2022: -$475K published
Month from 1 Apr 2022: $84K published
Month from 1 Feb 2023: $32K published
Month from 1 Feb 2025: -$4K published
Month from 1 Jan 2026: -$22K published
Month from 1 Nov 2026: -$122K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Jul 2025: 1 published
Revenue per quarter
Quarter ended 30 Jun 2021: $9.8M; public on 5 Aug 2022
Quarter ended 30 Sep 2021: $8.5M; public on 4 Nov 2022
Quarter ended 31 Dec 2021: $20.1M; public on 24 Feb 2023
Quarter ended 31 Mar 2022: $7.7M; public on 5 May 2023
Quarter ended 30 Jun 2022: $13.8M, +41% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $6.8M, -21% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $2.9M, -86% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $3.8M, -51% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $2.7M, -81% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $11.1M, +64% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $3.3M, +14% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $3.0M, -19% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $12.0M, +351% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $15.4M, +39% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $5.2M, +59% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $7.2M, +138% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $6.5M, -46% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $11.2M, -27% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $11.0M, +113% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $6.2M, -15% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $6.6M, +2.8% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $8.5M, -25% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $109K, -63% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $172K, -59% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $529K, -29% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $3.3M; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $1.5M, +1267% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $589K, +242% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $362K, -32% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $600K, -82% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $157K, -89% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 9 May 2024
Quarter ended 31 Mar 2025: $0; public on 13 May 2026
Quarter ended 30 Jun 2025: $185K; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $411K; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $64K; public on 13 May 2026
Quarter ended 30 Jun 2026: $37K, -80% on a year earlier; public on 12 Aug 2026
Institutional holders (13F filers)
31 Dec 2021 report: 108; public on 14 Feb 2022
31 Mar 2022 report: 118; public on 16 May 2022
30 Jun 2022 report: 107; public on 15 Aug 2022
30 Sep 2022 report: 106; public on 14 Nov 2022
31 Dec 2022 report: 105; public on 14 Feb 2023
31 Mar 2023 report: 115; public on 15 May 2023
30 Jun 2023 report: 92; public on 14 Aug 2023
30 Sep 2023 report: 77; public on 14 Nov 2023
31 Dec 2023 report: 89; public on 14 Feb 2024
31 Mar 2024 report: 101; public on 15 May 2024
30 Jun 2024 report: 106; public on 14 Aug 2024
30 Sep 2024 report: 111; public on 14 Nov 2024
31 Dec 2024 report: 110; public on 14 Feb 2025
31 Mar 2025 report: 112; public on 15 May 2025
30 Jun 2025 report: 94; public on 14 Aug 2025
30 Sep 2025 report: 91; public on 14 Nov 2025
31 Dec 2025 report: 97; public on 17 Feb 2026
31 Mar 2026 report: 120; public on 15 May 2026
30 Jun 2026 report: 147; public on 14 Aug 2026
30 Sep 2026 report: 147; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 34.0M shares sold short in the 14 Aug 2026 report, 8.2× the same report last year; it also had 37.4M shares sold short in the 31 Aug 2026 report, 9.9× the same report last year.
  • Short interest spike: had 21.3M shares sold short in the 15 May 2026 report, 3.3× the same report last year Public on 28 May 2026.
  • Insider net buying (open market): Insiders sold a net $145K in the last 12 months (the 12 months before: -$4K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 32 insider trades

Last 90 days: 1 sale, $122K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Nov 2026Kendra AdamsChief Financial OfficerSellplanned in advance (10b5-1)45,173$2.71$122KForm 4
16 Jan 2026Leonard ReynoChief Medical OfficerSell10,000$2.22$22KForm 4
18 Feb 2025Scott N BoyleChief Business OfficerSellplanned in advance (10b5-1)1,159$3.15$4KForm 4
10 Feb 2023Utpal KoppikarDirectorBuy5,667$5.60$32KForm 4
12 Apr 2022Andrew HirschPresident & CEOBuy10,000$8.40$84KForm 4
5 Jan 2022Adam CrystalChief Medical OfficerSellafter exercising options15,000$31.67$475KForm 4
17 Dec 2021Malcolm SalterDirectorSell755$30.25$23KForm 4
19 Nov 2021Malcolm SalterDirectorSell755$40.11$30KForm 4

147 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 23 opened a position, 23 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Squadron Capital Management LLC9.3M7.10%$31.0M+2.1M+29%
Morgan Stanley8.9M6.76%$29.5M+5,296+0.1%
Ra Capital Management, L.P.8.2M6.24%$27.3M+195K+2.4%
BlackRock, Inc.8.2M6.23%$27.2M+283K+3.6%
Lynx1 Capital Management LP7.5M5.73%$25.1M+204K+2.8%
Bain Capital Life Sciences Investors, LLC7.2M5.46%$23.9MNo change
Citadel Advisors LLC5.0M3.81%$16.7M+819K+20%
JPMorgan Chase & Co4.7M3.58%$14.7M-50K-1.1%
Goldman Sachs Group Inc4.7M3.57%$15.6M+1.2M+33%
Vanguard Capital Management LLC4.6M3.49%$15.3M+164K+3.7%

Company events

All 30 company events

In 12 months: 1 major agreement, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
15 May 2026Director or officer change8-K
9 Apr 2026Signed a major agreement8-K
16 Oct 2025Signed a major agreement8-K
14 Apr 2025Director or officer change8-K
20 Nov 2024Director or officer change8-K
15 Oct 2024Director or officer change8-K
11 Oct 2024Director or officer change8-K
3 Sep 2024Director or officer change8-K

6 open postings; careers site tracked since 21 Nov 2026. Most in Research & science 50%, Finance & accounting 17%, Marketing & communications 17%.

PostedJobLocation
4 Nov 2026Associate Director, Cell PharmacologyWatertown, MA, US
4 Nov 2026Scientist II, Cell PharmacologyResearch & scienceWatertown, MA, US
21 Oct 2026Associate Director, MarketingMarketing & communicationsWatertown, MA, US
19 Oct 2026Director, Assistant ControllerFinance & accountingWatertown, MA, US
16 Oct 2026Principal Scientist, Biology (Immunology)Research & scienceWatertown, MA, US
24 Sep 2026Principal Scientist, FormulationsResearch & scienceWatertown, MA, US

The 5 newest of 120 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

6 Aug 2024confirmed

Confirmed across sources Filings + Financials and Short interest and volume

C4 Therapeutics (CCCC): had 11.6M shares sold short in the 15 Jul 2024 report, 5.2× the same report last year, while it reported revenue of $12.0M for the quarter ended 30 Jun 2024, 4.5× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Short interest and volume: Short interest spike, became public on 25 Jul 2024
  • Financials: Quarterly revenue change, became public on 6 Aug 2024
2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M2024-04-30: 10.1M2024-05-15: 11.3M2024-05-31: 13.3M2024-06-14: 14.5M2024-06-28: 8.8M2024-07-15: 11.6M
The 15 Jul 2024 report against the 24 reports before it. this reportearliernormal: 3.3M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 25 Jul 2024

C4 Therapeutics had 11.6M shares sold short in the 15 Jul 2024 report, 5.2× the same report last year.

This period
11.6M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+4.1
Same report last year
2.2M
History used
1,369 days
2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M2024-04-30: 10.1M2024-05-15: 11.3M2024-05-31: 13.3M2024-06-14: 14.5M2024-06-28: 8.8M2024-07-15: 11.6M
the 15 Jul 2024 report24 earlier reportsnormal: 3.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 6 Aug 2024

C4 Therapeutics reported revenue of $12.0M for the quarter ended 30 Jun 2024, 4.5× the same quarter last year.

This period
$12.0M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$3.5M
Typical spread (median absolute deviation)
$751K
How far from its usual level
+7.6
Same quarter last year
$2.7M
History used
1,096 days
2022-06-30: $13.8M2022-09-30: $6.8M2022-12-31: $2.9M2023-03-31: $3.8M2023-06-30: $2.7M2023-09-30: $11.1M2023-12-31: $3.3M2024-03-31: $3.0M2024-06-30: $12.0M
the quarter ended 30 Jun 20248 earlier quartersnormal: $3.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 11 Sep 2026Short interest and volume change

    had 37.4M shares sold short in the 31 Aug 2026 report, 9.9× the same report last year.

    Same report last year: 3.8M; its normal report is 8.0M.

    See the evidence
    This period
    37.4M (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    8.0M
    Typical spread (median absolute deviation)
    4.4M
    How far from its usual level
    +4.5
    Same report last year
    3.8M
    History used
    2,146 days
    2025-08-29: 3.8M2025-09-15: 3.5M2025-09-30: 3.5M2025-10-15: 4.0M2025-10-31: 4.8M2025-11-14: 4.8M2025-11-28: 5.6M2025-12-15: 7.2M2025-12-31: 7.3M2026-01-15: 7.4M2026-01-30: 7.2M2026-02-13: 7.1M2026-02-27: 8.5M2026-03-13: 13.5M2026-03-31: 16.2M2026-04-15: 21.0M2026-04-30: 21.1M2026-05-15: 21.3M2026-05-29: 21.7M2026-06-15: 22.2M2026-06-30: 25.0M2026-07-15: 23.8M2026-07-31: 30.4M2026-08-14: 34.0M2026-08-31: 37.4M
    the 31 Aug 2026 report24 earlier reportsnormal: 8.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 26 Aug 2026Short interest and volume change

    had 34.0M shares sold short in the 14 Aug 2026 report, 8.2× the same report last year.

    Same report last year: 4.1M; its normal report is 7.3M.

    See the evidence
    This period
    34.0M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    7.3M
    Typical spread (median absolute deviation)
    3.7M
    How far from its usual level
    +4.9
    Same report last year
    4.1M
    History used
    2,129 days
    2025-08-15: 4.1M2025-08-29: 3.8M2025-09-15: 3.5M2025-09-30: 3.5M2025-10-15: 4.0M2025-10-31: 4.8M2025-11-14: 4.8M2025-11-28: 5.6M2025-12-15: 7.2M2025-12-31: 7.3M2026-01-15: 7.4M2026-01-30: 7.2M2026-02-13: 7.1M2026-02-27: 8.5M2026-03-13: 13.5M2026-03-31: 16.2M2026-04-15: 21.0M2026-04-30: 21.1M2026-05-15: 21.3M2026-05-29: 21.7M2026-06-15: 22.2M2026-06-30: 25.0M2026-07-15: 23.8M2026-07-31: 30.4M2026-08-14: 34.0M
    the 14 Aug 2026 report24 earlier reportsnormal: 7.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 12 Aug 2026Short interest and volume change

    had 30.4M shares sold short in the 31 Jul 2026 report, 6.5× the same report last year.

    Same report last year: 4.7M; its normal report is 7.2M.

    See the evidence
    This period
    30.4M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    7.2M
    Typical spread (median absolute deviation)
    3.4M
    How far from its usual level
    +4.7
    Same report last year
    4.7M
    History used
    2,115 days
    2025-07-31: 4.7M2025-08-15: 4.1M2025-08-29: 3.8M2025-09-15: 3.5M2025-09-30: 3.5M2025-10-15: 4.0M2025-10-31: 4.8M2025-11-14: 4.8M2025-11-28: 5.6M2025-12-15: 7.2M2025-12-31: 7.3M2026-01-15: 7.4M2026-01-30: 7.2M2026-02-13: 7.1M2026-02-27: 8.5M2026-03-13: 13.5M2026-03-31: 16.2M2026-04-15: 21.0M2026-04-30: 21.1M2026-05-15: 21.3M2026-05-29: 21.7M2026-06-15: 22.2M2026-06-30: 25.0M2026-07-15: 23.8M2026-07-31: 30.4M
    the 31 Jul 2026 report24 earlier reportsnormal: 7.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 10 Jun 2026Short interest and volume change

    had 21.7M shares sold short in the 29 May 2026 report, 3.5× the same report last year.

    Same report last year: 6.2M; its normal report is 6.3M.

    See the evidence
    This period
    21.7M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    6.3M
    Typical spread (median absolute deviation)
    1.9M
    How far from its usual level
    +5.5
    Same report last year
    6.2M
    History used
    2,052 days
    2025-05-30: 6.2M2025-06-13: 6.4M2025-06-30: 5.0M2025-07-15: 4.1M2025-07-31: 4.7M2025-08-15: 4.1M2025-08-29: 3.8M2025-09-15: 3.5M2025-09-30: 3.5M2025-10-15: 4.0M2025-10-31: 4.8M2025-11-14: 4.8M2025-11-28: 5.6M2025-12-15: 7.2M2025-12-31: 7.3M2026-01-15: 7.4M2026-01-30: 7.2M2026-02-13: 7.1M2026-02-27: 8.5M2026-03-13: 13.5M2026-03-31: 16.2M2026-04-15: 21.0M2026-04-30: 21.1M2026-05-15: 21.3M2026-05-29: 21.7M
    the 29 May 2026 report24 earlier reportsnormal: 6.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 28 May 2026Short interest and volume change

    had 21.3M shares sold short in the 15 May 2026 report, 3.3× the same report last year.

    Same report last year: 6.4M; its normal report is 6.3M.

    See the evidence
    This period
    21.3M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    6.3M
    Typical spread (median absolute deviation)
    1.5M
    How far from its usual level
    +6.6
    Same report last year
    6.4M
    History used
    2,038 days
    2025-05-15: 6.4M2025-05-30: 6.2M2025-06-13: 6.4M2025-06-30: 5.0M2025-07-15: 4.1M2025-07-31: 4.7M2025-08-15: 4.1M2025-08-29: 3.8M2025-09-15: 3.5M2025-09-30: 3.5M2025-10-15: 4.0M2025-10-31: 4.8M2025-11-14: 4.8M2025-11-28: 5.6M2025-12-15: 7.2M2025-12-31: 7.3M2026-01-15: 7.4M2026-01-30: 7.2M2026-02-13: 7.1M2026-02-27: 8.5M2026-03-13: 13.5M2026-03-31: 16.2M2026-04-15: 21.0M2026-04-30: 21.1M2026-05-15: 21.3M
    the 15 May 2026 report24 earlier reportsnormal: 6.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 15 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 15 May 2026Filings record

    Director or officer change

  8. 12 May 2026Short interest and volume change

    had 21.1M shares sold short in the 30 Apr 2026 report, 3.3× the same report last year.

    Same report last year: 6.4M; its normal report is 6.3M.

    See the evidence
    This period
    21.1M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    6.3M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +7.0
    Same report last year
    6.4M
    History used
    2,023 days
    2025-04-30: 6.4M2025-05-15: 6.4M2025-05-30: 6.2M2025-06-13: 6.4M2025-06-30: 5.0M2025-07-15: 4.1M2025-07-31: 4.7M2025-08-15: 4.1M2025-08-29: 3.8M2025-09-15: 3.5M2025-09-30: 3.5M2025-10-15: 4.0M2025-10-31: 4.8M2025-11-14: 4.8M2025-11-28: 5.6M2025-12-15: 7.2M2025-12-31: 7.3M2026-01-15: 7.4M2026-01-30: 7.2M2026-02-13: 7.1M2026-02-27: 8.5M2026-03-13: 13.5M2026-03-31: 16.2M2026-04-15: 21.0M2026-04-30: 21.1M
    the 30 Apr 2026 report24 earlier reportsnormal: 6.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 25 Apr 2026Short interest and volume change

    had 21.0M shares sold short in the 15 Apr 2026 report, 2.7× the same report last year.

    Same report last year: 7.7M; its normal report is 6.3M.

    See the evidence
    This period
    21.0M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    6.3M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +7.0
    Same report last year
    7.7M
    History used
    2,008 days
    2025-04-15: 7.7M2025-04-30: 6.4M2025-05-15: 6.4M2025-05-30: 6.2M2025-06-13: 6.4M2025-06-30: 5.0M2025-07-15: 4.1M2025-07-31: 4.7M2025-08-15: 4.1M2025-08-29: 3.8M2025-09-15: 3.5M2025-09-30: 3.5M2025-10-15: 4.0M2025-10-31: 4.8M2025-11-14: 4.8M2025-11-28: 5.6M2025-12-15: 7.2M2025-12-31: 7.3M2026-01-15: 7.4M2026-01-30: 7.2M2026-02-13: 7.1M2026-02-27: 8.5M2026-03-13: 13.5M2026-03-31: 16.2M2026-04-15: 21.0M
    the 15 Apr 2026 report24 earlier reportsnormal: 6.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 11 Apr 2026Short interest and volume change

    had 16.2M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.

    Same report last year: 7.8M; its normal report is 6.3M.

    See the evidence
    This period
    16.2M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    6.3M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +4.7
    Same report last year
    7.8M
    History used
    1,993 days
    2025-03-31: 7.8M2025-04-15: 7.7M2025-04-30: 6.4M2025-05-15: 6.4M2025-05-30: 6.2M2025-06-13: 6.4M2025-06-30: 5.0M2025-07-15: 4.1M2025-07-31: 4.7M2025-08-15: 4.1M2025-08-29: 3.8M2025-09-15: 3.5M2025-09-30: 3.5M2025-10-15: 4.0M2025-10-31: 4.8M2025-11-14: 4.8M2025-11-28: 5.6M2025-12-15: 7.2M2025-12-31: 7.3M2026-01-15: 7.4M2026-01-30: 7.2M2026-02-13: 7.1M2026-02-27: 8.5M2026-03-13: 13.5M2026-03-31: 16.2M
    the 31 Mar 2026 report24 earlier reportsnormal: 6.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 14 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 14 Apr 2025Filings record

    Director or officer change

  13. 20 Nov 2024Filings record

    Director or officer change

  14. 5 Nov 2024Financials change

    reported revenue of $15.4M for the quarter ended 30 Sep 2024, 1.4× the same quarter last year.

    Same quarter last year: $11.1M; its normal quarter is $3.5M.

    See the evidence
    This period
    $15.4M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $3.5M
    Typical spread (median absolute deviation)
    $751K
    How far from its usual level
    +10.6
    Same quarter last year
    $11.1M
    History used
    1,188 days
    2022-09-30: $6.8M2022-12-31: $2.9M2023-03-31: $3.8M2023-06-30: $2.7M2023-09-30: $11.1M2023-12-31: $3.3M2024-03-31: $3.0M2024-06-30: $12.0M2024-09-30: $15.4M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $3.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  15. 15 Oct 2024Filings record

    Director or officer change

  16. 11 Oct 2024Filings record

    Director or officer change

  17. 3 Sep 2024Filings record

    Director or officer change

  18. 6 Aug 2024several at once

    had 11.6M shares sold short in the 15 Jul 2024 report, 5.2× the same report last year, while it reported revenue of $12.0M for the quarter ended 30 Jun 2024, 4.5× the same quarter last year. Two unrelated kinds of activity within 7 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 25 Jul 2024

    C4 Therapeutics had 11.6M shares sold short in the 15 Jul 2024 report, 5.2× the same report last year.

    This period
    11.6M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +4.1
    Same report last year
    2.2M
    History used
    1,369 days
    2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M2024-04-30: 10.1M2024-05-15: 11.3M2024-05-31: 13.3M2024-06-14: 14.5M2024-06-28: 8.8M2024-07-15: 11.6M
    the 15 Jul 2024 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 6 Aug 2024

    C4 Therapeutics reported revenue of $12.0M for the quarter ended 30 Jun 2024, 4.5× the same quarter last year.

    This period
    $12.0M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $3.5M
    Typical spread (median absolute deviation)
    $751K
    How far from its usual level
    +7.6
    Same quarter last year
    $2.7M
    History used
    1,096 days
    2022-06-30: $13.8M2022-09-30: $6.8M2022-12-31: $2.9M2023-03-31: $3.8M2023-06-30: $2.7M2023-09-30: $11.1M2023-12-31: $3.3M2024-03-31: $3.0M2024-06-30: $12.0M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $3.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  19. 6 Aug 2024Financials change

    reported revenue of $12.0M for the quarter ended 30 Jun 2024, 4.5× the same quarter last year.

    Same quarter last year: $2.7M; its normal quarter is $3.5M.

    See the evidence
    This period
    $12.0M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $3.5M
    Typical spread (median absolute deviation)
    $751K
    How far from its usual level
    +7.6
    Same quarter last year
    $2.7M
    History used
    1,096 days
    2022-06-30: $13.8M2022-09-30: $6.8M2022-12-31: $2.9M2023-03-31: $3.8M2023-06-30: $2.7M2023-09-30: $11.1M2023-12-31: $3.3M2024-03-31: $3.0M2024-06-30: $12.0M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $3.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  20. 25 Jul 2024Short interest and volume change

    had 11.6M shares sold short in the 15 Jul 2024 report, 5.2× the same report last year.

    Same report last year: 2.2M; its normal report is 3.3M.

    See the evidence
    This period
    11.6M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +4.1
    Same report last year
    2.2M
    History used
    1,369 days
    2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M2024-04-30: 10.1M2024-05-15: 11.3M2024-05-31: 13.3M2024-06-14: 14.5M2024-06-28: 8.8M2024-07-15: 11.6M
    the 15 Jul 2024 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 27 Jun 2024Short interest and volume change

    had 14.5M shares sold short in the 14 Jun 2024 report, 4.4× the same report last year.

    Same report last year: 3.3M; its normal report is 3.1M.

    See the evidence
    This period
    14.5M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +6.6
    Same report last year
    3.3M
    History used
    1,338 days
    2023-06-15: 3.3M2023-06-30: 2.5M2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M2024-04-30: 10.1M2024-05-15: 11.3M2024-05-31: 13.3M2024-06-14: 14.5M
    the 14 Jun 2024 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 12 Jun 2024Short interest and volume change

    had 13.3M shares sold short in the 31 May 2024 report, 4.1× the same report last year.

    Same report last year: 3.2M; its normal report is 3.1M.

    See the evidence
    This period
    13.3M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +6.0
    Same report last year
    3.2M
    History used
    1,324 days
    2023-05-31: 3.2M2023-06-15: 3.3M2023-06-30: 2.5M2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M2024-04-30: 10.1M2024-05-15: 11.3M2024-05-31: 13.3M
    the 31 May 2024 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 10 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 10 Jun 2024Filings record

    Director or officer change

  25. 25 May 2024Short interest and volume change

    had 11.3M shares sold short in the 15 May 2024 report, 3.9× the same report last year.

    Same report last year: 2.9M; its normal report is 2.9M.

    See the evidence
    This period
    11.3M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    2.9M
    Typical spread (median absolute deviation)
    913K
    How far from its usual level
    +6.2
    Same report last year
    2.9M
    History used
    1,308 days
    2023-05-15: 2.9M2023-05-31: 3.2M2023-06-15: 3.3M2023-06-30: 2.5M2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M2024-04-30: 10.1M2024-05-15: 11.3M
    the 15 May 2024 report24 earlier reportsnormal: 2.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 10 May 2024Short interest and volume change

    had 10.1M shares sold short in the 30 Apr 2024 report, 3.5× the same report last year.

    Same report last year: 2.9M; its normal report is 2.9M.

    See the evidence
    This period
    10.1M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    2.9M
    Typical spread (median absolute deviation)
    795K
    How far from its usual level
    +6.2
    Same report last year
    2.9M
    History used
    1,293 days
    2023-04-28: 2.9M2023-05-15: 2.9M2023-05-31: 3.2M2023-06-15: 3.3M2023-06-30: 2.5M2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M2024-04-30: 10.1M
    the 30 Apr 2024 report24 earlier reportsnormal: 2.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 25 Apr 2024Short interest and volume change

    had 9.6M shares sold short in the 15 Apr 2024 report, 3.4× the same report last year.

    Same report last year: 2.8M; its normal report is 2.9M.

    See the evidence
    This period
    9.6M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    2.9M
    Typical spread (median absolute deviation)
    681K
    How far from its usual level
    +6.6
    Same report last year
    2.8M
    History used
    1,278 days
    2023-04-14: 2.8M2023-04-28: 2.9M2023-05-15: 2.9M2023-05-31: 3.2M2023-06-15: 3.3M2023-06-30: 2.5M2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M2024-04-15: 9.6M
    the 15 Apr 2024 report24 earlier reportsnormal: 2.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 10 Apr 2024Short interest and volume change

    had 9.1M shares sold short in the 28 Mar 2024 report, 3.5× the same report last year.

    Same report last year: 2.6M; its normal report is 2.7M.

    See the evidence
    This period
    9.1M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    617K
    How far from its usual level
    +7.0
    Same report last year
    2.6M
    History used
    1,260 days
    2023-03-31: 2.6M2023-04-14: 2.8M2023-04-28: 2.9M2023-05-15: 2.9M2023-05-31: 3.2M2023-06-15: 3.3M2023-06-30: 2.5M2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M2023-12-29: 4.5M2024-01-12: 5.6M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.0M2024-03-15: 5.3M2024-03-28: 9.1M
    the 28 Mar 2024 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 8 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 8 Mar 2024Filings record

    Director or officer change

  31. 9 Jan 2024Filings record

    Restructuring costs announced

  32. 28 Dec 2023Short interest and volume change

    had 8.1M shares sold short in the 15 Dec 2023 report, 2.2× the same report last year.

    Same report last year: 3.6M; its normal report is 2.7M.

    See the evidence
    This period
    8.1M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    569K
    How far from its usual level
    +6.4
    Same report last year
    3.6M
    History used
    1,156 days
    2022-12-15: 3.6M2022-12-30: 3.5M2023-01-13: 3.6M2023-01-31: 3.7M2023-02-15: 3.2M2023-02-28: 3.3M2023-03-15: 2.9M2023-03-31: 2.6M2023-04-14: 2.8M2023-04-28: 2.9M2023-05-15: 2.9M2023-05-31: 3.2M2023-06-15: 3.3M2023-06-30: 2.5M2023-07-14: 2.2M2023-07-31: 2.1M2023-08-15: 1.9M2023-08-31: 2.1M2023-09-15: 2.4M2023-09-29: 2.3M2023-10-13: 1.8M2023-10-31: 1.9M2023-11-15: 2.0M2023-11-30: 1.9M2023-12-15: 8.1M
    the 15 Dec 2023 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 20 Nov 2023Filings record

    Director or officer change

  34. 5 Sep 2023Filings record

    Director or officer change

  35. 20 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 20 Jun 2023Filings record

    Director or officer change

  37. 11 Feb 2023Insiders record

    Koppikar Utpal (director) bought 5,667 shares of CCCC ($31,735) (dated 10 Feb 2023)

  38. 2 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 2 Feb 2023Filings record

    Director or officer change

  40. 2 Aug 2022Filings record

    Director or officer change

Showing the newest 40 of 68 entries; narrow the window or the kind of data to see older ones.

Not listed: 99 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001662579
Ticker
CCCC
Domain
c4therapeutics.com
Employer name
C4 THERAPEUTICS, INC. (1 unverified)
Hq location
MA|WATERTOWN|02472 (1 unverified)
Name
C4 Therapeutics, Inc., C4T Securities Corporation, Document, EX-21.1
Wikidata
Q64142088
  • DOL H-1B labor condition applications and PERM certifications35 data points1 Oct 2019 to 9 Jun 2025
  • SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)96 records11 Jan 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)466 data points31 Dec 2018 to 30 Oct 2026
  • SEC Form 4 insider transactions32 records, 96 data points6 Oct 2020 to 13 Nov 2026
  • FINRA short interest (twice monthly)434 data points15 Oct 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3084 data points2 Oct 2020 to 20 Nov 2026